Company Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Sanofi and Regeneron Announce New Praluent® (alirocumab) Injection Analyses Presented at AHA Scientific Sessions 2015

[PR Newswire] – BRIDGEWATER, N.J. and TARRYTOWN, N.Y., Nov. 10, 2015 /PRNewswire/ — Sanofi and Regeneron Pharmaceuticals, Inc. today announced a new post-hoc analysis of six Phase 3 clinical trials showing that approximately . . . → Read More: Company Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Sanofi and Regeneron Announce New Praluent® (alirocumab) Injection Analyses Presented at AHA Scientific Sessions 2015 Similar Articles: Stock Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Regeneron and Sanofi Announce New Positive Praluent® (alirocumab) Phase 3 Data Presented at ESC Congress 2015 Company Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia Market Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the American Thoracic Society 2015 International Conference